Cann Group Limited is an Australian healthcare company specializing in the breeding, cultivation, manufacturing, and sale of medicinal cannabis products. Its core function revolves around developing and supplying pharmaceutical-grade cannabis for therapeutic applications, as well as conducting research under regulated licenses and permits. Cann Group supports both end-use patients and the broader healthcare industry by manufacturing finished formulations through third-party arrangements and distributing them in Australia and Europe, thereby contributing to the growth and innovation in the specialty and generic drug sector. The company plays a pivotal role within the medicinal cannabis industry, advancing cultivation techniques and research-backed product development for a range of medical conditions. Founded in 2014 and headquartered in Melbourne, Cann Group Limited operates with a focus on compliance, scientific research, and strategic supply agreements that bolster its market significance within the evolving medical cannabis landscape.